Researchers have long focused on the brain when searching for the causes of Alzheimer's disease, looking at plaques and damaged neurons. But a new study suggests that part of the damage might originate outside the skull, in the neck's lymph nodes. A team from the School of Medicine at Washington University in St. Louis published their findings in Nature Neuroscience on September 3, 2026, revealing a previously unexplored link between the immune system and the progression of Alzheimer's. This research highlights that brain lesions associated with the tau protein—another key player in Alzheimer's—are worsened by immune cells from the body's defense system. In forms of Alzheimer's involving the tau protein, the destruction of neurons is not solely the result of tau clusters. In mice genetically modified to accumulate these tangles, researchers observed an invasion of CD8 T lymphocytes—killer immune cells—that accumulate in the brain at abnormal levels and accelerate degeneration. Normally, these cells are responsible for identifying and attacking viruses and infected cells. In this case, they mistakenly target the nervous system. This finding suggests that part of the damage in Alzheimer's may come from the immune system itself, not just from the protein. To test this theory, researchers interrupted the chain of events by depriving these killer cells of their instructions. Without guidance, the cells stopped attacking, and brain lesions significantly receded. Importantly, the tau tangles themselves remained in place, showing that the protein alone does not fully explain the damage. The signals directing these immune cells originate from the lymph nodes in the neck, which act as filters for the immune system. There, dendritic cells called cDC1, which are like sentinels, are believed to detect tau debris transported from the brain via the lymphatic system. These sentinels then guide T lymphocytes to attack the brain. To test this scenario, researchers eliminated dendritic cells in mice. The usual rise of lymphocytes in the brain disappeared, and the animals maintained their cognitive abilities, indicating a possible way to slow the decline rather than just manage it. This discovery opens a new and unexpected treatment path for Alzheimer's. Because the responsible cells are located outside the nervous system, future drugs may not need to cross the blood-brain barrier, a protective filter that stops most molecules from entering the brain. According to David Holtzman, who led the study, "it may not be necessary to get drugs into the brain to slow neurodegeneration." Techniques to influence T lymphocytes are already used in cancer treatment. However, caution is needed before drawing conclusions. While doctors know how to manipulate these cells using approved immunotherapies for other diseases, none have been tested against dementia. There is no guarantee that the mechanism works the same way in humans, as the study so far relies on mouse models and human tissue samples. The team is now investigating whether blocking these cells in older individuals provides the same protective benefits as early intervention.